Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Vigil files to sell 10.28M shares of common stock, warrants for holders  16:06
09/30/22
09/30
16:06
09/30/22
16:06
VIGL

Vigil Neuroscience

$9.00 /

+0.06 (+0.67%)

 
ShowHide Related Items >><<
VIGL Vigil Neuroscience
$9.00 /

+0.06 (+0.67%)

VIGL Vigil Neuroscience
$9.00 /

+0.06 (+0.67%)

09/15/22 Wedbush
Vigil Neuroscience initiated with an Outperform at Wedbush
09/15/22 Wedbush
Vigil Neuroscience initiated with an Outperform at Wedbush
08/29/22 H.C. Wainwright
Vigil Neuroscience initiated with a Buy at H.C. Wainwright
02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
VIGL Vigil Neuroscience
$9.00 /

+0.06 (+0.67%)

  • 07
    Jan
VIGL Vigil Neuroscience
$9.00 /

+0.06 (+0.67%)

On The Fly
Sell these stocks now, proven algorithm says » 15:43
09/30/22
09/30
15:43
09/30/22
15:43
STEM

Stem

$13.37 /

+0.405 (+3.12%)

, U

Unity

$32.17 /

+0.395 (+1.24%)

, BILI

Bilibili

$15.38 /

+0.14 (+0.92%)

, LFG

Archaea Energy

$18.17 /

+0.19 (+1.06%)

, FTCH

Farfetch

$7.44 /

-0.12 (-1.59%)

, ISEE

Iveric bio

$18.27 /

+0.95 (+5.48%)

, IRT

Independence Realty Trust

$16.67 /

+0.43 (+2.65%)

This week's downgrades to…

ShowHide Related Items >><<
U Unity
$32.17 /

+0.395 (+1.24%)

STEM Stem
$13.37 /

+0.405 (+3.12%)

LFG Archaea Energy
$18.17 /

+0.19 (+1.06%)

ISEE Iveric bio
$18.27 /

+0.95 (+5.48%)

IRT Independence Realty Trust
$16.67 /

+0.43 (+2.65%)

FTCH Farfetch
$7.44 /

-0.12 (-1.59%)

BILI Bilibili
$15.38 /

+0.14 (+0.92%)

STEM Stem
$13.37 /

+0.405 (+3.12%)

09/29/22 Guggenheim
Stem price target raised to $17 at Guggenheim after analyst day
09/29/22 Susquehanna
Stem guidance shows acceleration in sales, says Susquehanna
09/29/22 Cowen
Stem price target lowered to $20 from $22 at Cowen
09/22/22 Cowen
Cowen starts Stem with an Outperform, calls it a top pick
U Unity
$32.17 /

+0.395 (+1.24%)

09/30/22 BofA
Unity reinstated with a Neutral, $40 target at BofA
09/30/22 BofA
Unity reinstated with a Neutral at BofA
09/13/22 Oppenheimer
AppLovin price target lowered to $45 from $65 at Oppenheimer
09/13/22 William Blair
AppLovin still 'formidable competitor' without Unity, says William Blair
BILI Bilibili
$15.38 /

+0.14 (+0.92%)

09/09/22 Benchmark
Bilibili price target lowered to $30 from $56 at Benchmark
09/09/22 UBS
Bilibili price target lowered to $30 from $40 at UBS
09/09/22 Barclays
Bilibili price target lowered to $21 from $26 at Barclays
09/08/22 Citi
Bilibili price target lowered to $38 from $45 at Citi
LFG Archaea Energy
$18.17 /

+0.19 (+1.06%)

06/17/22 Barclays
Barclays starts Archaea Energy at Overweight on 'vast' growth potential
06/17/22 Barclays
Archaea Energy initiated with an Overweight at Barclays
03/07/22 Stifel
Archaea Energy initiated with a Buy and placed on Select List at Stifel
01/18/22 Citi
Archaea Energy price target lowered to $29 from $31 at Citi
FTCH Farfetch
$7.44 /

-0.12 (-1.59%)

09/26/22 Citi
Farfetch initiated with a Sell at Citi
08/30/22 Cowen
Farfetch price target raised to $11 from $9 at Cowen
08/26/22 Morgan Stanley
Morgan Stanley bumps up Farfetch target, says guide down may be 'clearing event'
08/26/22 KeyBanc
Farfetch price target raised to $13 from $11 at KeyBanc
ISEE Iveric bio
$18.27 /

+0.95 (+5.48%)

09/08/22 Stifel
Apellis price target raised to $65 from $60 at Stifel
09/08/22 Stifel
Iveric bio price target raised to $35 from $28 at Stifel
09/07/22 Guggenheim
Iveric bio price target raised to $35 from $30 at Guggenheim
09/07/22 Baird
Iveric bio price target raised to $34 from $27 at Baird
IRT Independence Realty Trust
$16.67 /

+0.43 (+2.65%)

06/30/22 Jefferies
Independence Realty Trust price target lowered to $24 from $27 at Jefferies
05/10/22 Barclays
Independence Realty Trust price target lowered to $28 from $30 at Barclays
05/09/22 BTIG
Independence Realty Trust assumed with a Buy at BTIG
04/22/22 Jefferies
Independence Realty Trust initiated with a Buy at Jefferies
U Unity
$32.17 /

+0.395 (+1.24%)

STEM Stem
$13.37 /

+0.405 (+3.12%)

LFG Archaea Energy
$18.17 /

+0.19 (+1.06%)

ISEE Iveric bio
$18.27 /

+0.95 (+5.48%)

IRT Independence Realty Trust
$16.67 /

+0.43 (+2.65%)

FTCH Farfetch
$7.44 /

-0.12 (-1.59%)

BILI Bilibili
$15.38 /

+0.14 (+0.92%)

  • 23
    Mar
  • 22
    Oct
U Unity
$32.17 /

+0.395 (+1.24%)

FTCH Farfetch
$7.44 /

-0.12 (-1.59%)

BILI Bilibili
$15.38 /

+0.14 (+0.92%)

U Unity
$32.17 /

+0.395 (+1.24%)

STEM Stem
$13.37 /

+0.405 (+3.12%)

LFG Archaea Energy
$18.17 /

+0.19 (+1.06%)

ISEE Iveric bio
$18.27 /

+0.95 (+5.48%)

IRT Independence Realty Trust
$16.67 /

+0.43 (+2.65%)

FTCH Farfetch
$7.44 /

-0.12 (-1.59%)

BILI Bilibili
$15.38 /

+0.14 (+0.92%)

U Unity
$32.17 /

+0.395 (+1.24%)

STEM Stem
$13.37 /

+0.405 (+3.12%)

ISEE Iveric bio
$18.27 /

+0.95 (+5.48%)

FTCH Farfetch
$7.44 /

-0.12 (-1.59%)

BILI Bilibili
$15.38 /

+0.14 (+0.92%)

Thursday
Conference/Events
Neurocrine to participate in a conference call with JPMorgan » 12:55
09/29/22
09/29
12:55
09/29/22
12:55
NBIX

Neurocrine

$101.63 /

-1.195 (-1.16%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Gorman on September 29 at 1:30 pm hosted by JPMorgan.

ShowHide Related Items >><<
NBIX Neurocrine
$101.63 /

-1.195 (-1.16%)

NBIX Neurocrine
$101.63 /

-1.195 (-1.16%)

09/26/22 Wells Fargo
Neurocrine initiated with an Equal Weight at Wells Fargo
08/08/22 Mizuho
Neurocrine price target raised to $98 from $95 at Mizuho
08/05/22 Baird
Neurocrine price target raised to $125 from $117 at Baird
08/05/22 Barclays
Neurocrine price target raised to $113 from $110 at Barclays
NBIX Neurocrine
$101.63 /

-1.195 (-1.16%)

NBIX Neurocrine
$101.63 /

-1.195 (-1.16%)

Hot Stocks
Neurocrine appoints Ingrid Delaet as CRO » 11:02
09/29/22
09/29
11:02
09/29/22
11:02
NBIX

Neurocrine

$100.69 /

-2.13 (-2.07%)

, ICPT

Intercept

$16.48 /

-0.55 (-3.23%)

Neurocrine Biosciences…

Neurocrine Biosciences (NBIX) announced that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.Prior to joining Neurocrine Biosciences, Dr. Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals (ICPT), which she joined in 2016.

ShowHide Related Items >><<
NBIX Neurocrine
$100.69 /

-2.13 (-2.07%)

ICPT Intercept
$16.48 /

-0.55 (-3.23%)

NBIX Neurocrine
$100.69 /

-2.13 (-2.07%)

09/26/22 Wells Fargo
Neurocrine initiated with an Equal Weight at Wells Fargo
08/08/22 Mizuho
Neurocrine price target raised to $98 from $95 at Mizuho
08/05/22 Baird
Neurocrine price target raised to $125 from $117 at Baird
08/05/22 Barclays
Neurocrine price target raised to $113 from $110 at Barclays
ICPT Intercept
$16.48 /

-0.55 (-3.23%)

08/22/22 B. Riley
Intercept's 'transformational' moves being underappreciated, says B. Riley
08/08/22 H.C. Wainwright
Intercept price target lowered to $16 from $18 at H.C. Wainwright
08/03/22 Piper Sandler
Piper Sandler remains bullish on Intercept into NDA resubmission of OCA
07/08/22 Needham
Intercept price target lowered to $22 from $25 at Needham
NBIX Neurocrine
$100.69 /

-2.13 (-2.07%)

ICPT Intercept
$16.48 /

-0.55 (-3.23%)

NBIX Neurocrine
$100.69 /

-2.13 (-2.07%)

ICPT Intercept
$16.48 /

-0.55 (-3.23%)

Recommendations
Karuna Therapeutics price target raised to $293 from $292 at RBC Capital » 06:28
09/29/22
09/29
06:28
09/29/22
06:28
KRTX

Karuna Therapeutics

$225.26 /

+3.04 (+1.37%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Karuna Therapeutics to $293 from $292 and keeps an Outperform rating on the shares after speaking with a patent attorney specializing in biotech IP life. The analyst says the company's Patent Family 1 is "strong" and regulatory exclusivity should provide further protection, adding that the expert also believes that Karuna's Patent Family 2 can extend protection to 2040 with limited ways for generics to circumvent it.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$225.26 /

+3.04 (+1.37%)

KRTX Karuna Therapeutics
$225.26 /

+3.04 (+1.37%)

09/26/22 Wells Fargo
Cerevel Therapeutics initiated with an Overweight at Wells Fargo
09/13/22 Stifel
Karuna Therapeutics price target raised to $295 from $260 at Stifel
08/23/22 Mizuho
Cerevel Therapeutics price target raised to $32 from $27 at Mizuho
08/18/22 Wedbush
Karuna Therapeutics removed from Best Ideas List at Wedbush
KRTX Karuna Therapeutics
$225.26 /

+3.04 (+1.37%)

  • 10
    Aug
  • 10
    Nov
KRTX Karuna Therapeutics
$225.26 /

+3.04 (+1.37%)

Conference/Events
Neurocrine to participate in a conference call with JPMorgan » 04:55
09/29/22
09/29
04:55
09/29/22
04:55
NBIX

Neurocrine

$102.82 /

+1.39 (+1.37%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Gorman on September 29 at 1:30 pm hosted by JPMorgan.

ShowHide Related Items >><<
NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

09/26/22 Wells Fargo
Neurocrine initiated with an Equal Weight at Wells Fargo
08/08/22 Mizuho
Neurocrine price target raised to $98 from $95 at Mizuho
08/05/22 Baird
Neurocrine price target raised to $125 from $117 at Baird
08/05/22 Barclays
Neurocrine price target raised to $113 from $110 at Barclays
NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

Conference/Events
Guggenheim to hold a conference » 04:55
09/29/22
09/29
04:55
09/29/22
04:55
RPTX

Repare Therapeutics

$12.42 /

+0.56 (+4.72%)

, IMGN

ImmunoGen

$4.72 /

+0.08 (+1.72%)

, CNTA

Centessa

$4.62 /

+0.115 (+2.55%)

, KYMR

Kymera Therapeutics

$22.72 /

+1.1 (+5.09%)

, MGNX

MacroGenics

$3.65 /

+0.155 (+4.44%)

, SEEL

Seelos Therapeutics

$1.17 /

+0.12 (+11.43%)

, GLUE

Monte Rosa Therapeutics

$8.34 /

+0.575 (+7.41%)

, NTLA

Intellia Therapeutics

$58.66 /

+2.585 (+4.61%)

, EYPT

EyePoint

$7.65 /

+0.645 (+9.21%)

, IMPL

Impel Pharmaceuticals

$5.67 /

+0.24 (+4.42%)

, RUBY

Rubius Therapeutics

/

+

Nantucket Therapeutics…

Nantucket Therapeutics Conference to be held in New York on September 27-29. Webcast Link

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$1.17 /

+0.12 (+11.43%)

RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

MGNX MacroGenics
$3.65 /

+0.155 (+4.44%)

KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

IMGN ImmunoGen
$4.72 /

+0.08 (+1.72%)

GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

06/06/22 H.C. Wainwright
Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright
06/02/22 Piper Sandler
Piper ups Repare Therapeutics target after 'great deal' with Roche
04/12/22 Stifel
Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis'
04/12/22 Stifel
Repare Therapeutics downgraded to Hold from Buy at Stifel
IMGN ImmunoGen
$4.72 /

+0.08 (+1.72%)

09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
03/21/22 RBC Capital
ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital
CNTA Centessa
$4.62 /

+0.115 (+2.55%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
MGNX MacroGenics
$3.65 /

+0.155 (+4.44%)

09/12/22 H.C. Wainwright
MacroGenics price target lowered to $10 from $35 at H.C. Wainwright
08/29/22 Citi
MacroGenics price target raised to $16 from $13 at Citi
08/09/22 Barclays
MacroGenics price target lowered to $8 from $18 at Barclays
07/11/22 BTIG
MacroGenics price target lowered to $6 at BTIG
SEEL Seelos Therapeutics
$1.17 /

+0.12 (+11.43%)

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

08/15/22 Jefferies
Monte Rosa Therapeutics initiated with a Buy at Jefferies
05/11/22 Piper Sandler
Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler
04/28/22 Credit Suisse
Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse
04/08/22 Piper Sandler
Piper keeps Overweight rating on Monte Rosa Therapeutics after AACR abstract
NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

09/21/22 JPMorgan
JPMorgan starts Intellia with Overweight, adds to Focus List
09/21/22 JPMorgan
Intellia Therapeutics initiated with an Overweight at JPMorgan
09/19/22 JMP Securities
Intellia Therapeutics price target raised to $111 from $106 at JMP Securities
09/19/22 Citi
Citi keeps Sell rating, $50 target on Intellia Therapeutics after data
EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
11/16/21 Cantor Fitzgerald
EyePoint stock movement unwarranted, says Cantor Fitzgerald
IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

08/24/22 JonesTrading
Impel Pharmaceuticals initiated with a Buy at JonesTrading
RUBY Rubius Therapeutics
/

+

09/13/22 Guggenheim
Rubius downgraded at Guggenheim after discontinuation of all clinical programs
09/13/22 Guggenheim
Rubius Therapeutics downgraded to Neutral from Buy at Guggenheim
05/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $8 from $15 at H.C. Wainwright
04/11/22 Morgan Stanley
Rubius Therapeutics price target lowered to $4 from $15 at Morgan Stanley
RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

MGNX MacroGenics
$3.65 /

+0.155 (+4.44%)

KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

IMGN ImmunoGen
$4.72 /

+0.08 (+1.72%)

GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

  • 02
    Dec
  • 17
    Nov
  • 28
    Oct
NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

SEEL Seelos Therapeutics
$1.17 /

+0.12 (+11.43%)

GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

Wednesday
Conference/Events
Neurocrine to participate in a conference call with JPMorgan » 17:21
09/28/22
09/28
17:21
09/28/22
17:21
NBIX

Neurocrine

$102.82 /

+1.39 (+1.37%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Gorman on September 29 at 1:30 pm hosted by JPMorgan.

ShowHide Related Items >><<
NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

09/26/22 Wells Fargo
Neurocrine initiated with an Equal Weight at Wells Fargo
08/08/22 Mizuho
Neurocrine price target raised to $98 from $95 at Mizuho
08/05/22 Baird
Neurocrine price target raised to $125 from $117 at Baird
08/05/22 Barclays
Neurocrine price target raised to $113 from $110 at Barclays
NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

Conference/Events
Cantor Fitzgerald healthcare analysts to hold KOL luncheon panel » 12:15
09/28/22
09/28
12:15
09/28/22
12:15
AZN

AstraZeneca

$54.47 /

+1.22 (+2.29%)

, AMGN

Amgen

$229.80 /

+3.76 (+1.66%)

, MRTX

Mirati Therapeutics

$69.30 /

+1.71 (+2.53%)

, GILD

Gilead

$63.70 /

+1.07 (+1.71%)

, IMAB

I-Mab

$4.77 /

+0.17 (+3.70%)

, NVS

Novartis

$76.49 /

+1.84 (+2.46%)

, SURF

Surface Oncology

$1.11 /

+0.075 (+7.25%)

, PFE

Pfizer

$44.50 /

+0.35 (+0.79%)

, ALXO

ALX Oncology

$9.99 /

+0.58 (+6.16%)

, RHHBY

Roche

$39.05 /

+0.36 (+0.93%)

, MRK

Merck

$86.46 /

+0.59 (+0.69%)

In conjunction with…

In conjunction with Cantor's Oncology, Hematology & HemeOnc Conference, Cantor's Healthcare Analysts, along with Dr. Vijayvergia, Associate Professor at Fox Chase Cancer Center & Dr. Sabari, Asst Professor at NYU Langone Medical Center, participate in an Immuno-Oncology & Solid Tumor KOL Luncheon Panel being held in New York on September 28 at 12:30 pm.

ShowHide Related Items >><<
SURF Surface Oncology
$1.11 /

+0.075 (+7.25%)

RHHBY Roche
$39.05 /

+0.36 (+0.93%)

PFE Pfizer
$44.50 /

+0.35 (+0.79%)

NVS Novartis
$76.49 /

+1.84 (+2.46%)

MRTX Mirati Therapeutics
$69.30 /

+1.71 (+2.53%)

MRK Merck
$86.46 /

+0.59 (+0.69%)

IMAB I-Mab
$4.77 /

+0.17 (+3.70%)

GILD Gilead
$63.70 /

+1.07 (+1.71%)

AZN AstraZeneca
$54.47 /

+1.22 (+2.29%)

AMGN Amgen
$229.80 /

+3.76 (+1.66%)

ALXO ALX Oncology
$9.99 /

+0.58 (+6.16%)

AZN AstraZeneca
$54.47 /

+1.22 (+2.29%)

09/15/22 Credit Suisse
AstraZeneca downgraded to Neutral from Outperform at Credit Suisse
09/07/22 Morgan Stanley
AstraZeneca downgraded to Equal Weight from Overweight at Morgan Stanley
08/29/22 Argus
Argus upgrades AstraZeneca to Buy on 'impressive growth' and higher margins
08/29/22 Argus
AstraZeneca upgraded to Buy from Hold at Argus
AMGN Amgen
$229.80 /

+3.76 (+1.66%)

08/08/22 Piper Sandler
Amgen combo data for Lumakras disappoints, says Piper Sandler
08/08/22 JMP Securities
Mirati Therapeutics price target raised to $110 from $90 at JMP Securities
08/05/22 RBC Capital
Amgen price target raised to $236 from $224 at RBC Capital
08/05/22 Piper Sandler
Amgen price target raised to $265 from $260 at Piper Sandler
MRTX Mirati Therapeutics
$69.30 /

+1.71 (+2.53%)

09/26/22 JPMorgan
Mirati Therapeutics price target lowered to $94 from $109 at JPMorgan
09/15/22 Piper Sandler
Mirati Therapeutics initiated with an Overweight at Piper Sandler
08/08/22 Stifel
Global Blood Therapeutics downgraded to Hold from Buy at Stifel
08/08/22 BofA
Mirati Therapeutics price target raised to $88 from $79 at BofA
GILD Gilead
$63.70 /

+1.07 (+1.71%)

09/20/22 Piper Sandler
Piper says Merck partial hold being lifted a positive update for Gilead
09/15/22 Truist
Gilead price target raised to $76 from $71 at Truist
09/13/22 Wells Fargo
Gilead price target raised to $74 from $63 at Wells Fargo
09/12/22 Piper Sandler
Gilead price target raised to $79 from $74 at Piper Sandler
IMAB I-Mab
$4.77 /

+0.17 (+3.70%)

08/31/22 H.C. Wainwright
I-Mab price target lowered to $45 from $70 at H.C. Wainwright
08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
05/31/22 H.C. Wainwright
I-Mab price target lowered to $70 from $80 at H.C. Wainwright
05/27/22 Piper Sandler
I-Mab price target lowered to $35 from $80 at Piper Sandler
NVS Novartis
$76.49 /

+1.84 (+2.46%)

09/15/22 Credit Suisse
Novartis downgraded to Underperform from Neutral at Credit Suisse
09/14/22 Berenberg
Novartis downgraded to Hold from Buy at Berenberg
09/07/22 Morgan Stanley
Novartis price target lowered to CHF 88 from CHF 97 at Morgan Stanley
09/07/22 Kepler Cheuvreux
Novartis upgraded to Buy from Hold at Kepler Cheuvreux
SURF Surface Oncology
$1.11 /

+0.075 (+7.25%)

08/08/22 H.C. Wainwright
Surface Oncology price target lowered to $8.50 from $10 at H.C. Wainwright
PFE Pfizer
$44.50 /

+0.35 (+0.79%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
ALXO ALX Oncology
$9.99 /

+0.58 (+6.16%)

08/09/22 Cantor Fitzgerald
ALX Oncology price target lowered to $32 from $60 at Cantor Fitzgerald
08/09/22 Credit Suisse
ALX Oncology price target lowered to $38 from $43 at Credit Suisse
06/06/22 Stifel
ALX Oncology price target lowered to $16 from $35 at Stifel
06/03/22 Piper Sandler
ALX's evorpacept best-in-class aong CD47-targeting agents, says Piper Sandler
RHHBY Roche
$39.05 /

+0.36 (+0.93%)

09/15/22 Ladenburg
Tempest Therapeutics initiated with a Buy at Ladenburg
09/15/22 Credit Suisse
Roche upgraded to Outperform from Neutral at Credit Suisse
09/14/22 Berenberg
Roche upgraded to Buy from Hold at Berenberg
09/08/22 Piper Sandler
Regeneron data 'game changing,' will drive market share, says Piper
MRK Merck
$86.46 /

+0.59 (+0.69%)

09/14/22 Berenberg
Merck upgraded to Buy from Hold at Berenberg
08/25/22 Erste Group
Merck upgraded to Buy from Hold at Erste Group
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
SURF Surface Oncology
$1.11 /

+0.075 (+7.25%)

RHHBY Roche
$39.05 /

+0.36 (+0.93%)

PFE Pfizer
$44.50 /

+0.35 (+0.79%)

NVS Novartis
$76.49 /

+1.84 (+2.46%)

MRTX Mirati Therapeutics
$69.30 /

+1.71 (+2.53%)

MRK Merck
$86.46 /

+0.59 (+0.69%)

GILD Gilead
$63.70 /

+1.07 (+1.71%)

AZN AstraZeneca
$54.47 /

+1.22 (+2.29%)

AMGN Amgen
$229.80 /

+3.76 (+1.66%)

ALXO ALX Oncology
$9.99 /

+0.58 (+6.16%)

  • 11
    Nov
PFE Pfizer
$44.50 /

+0.35 (+0.79%)

NVS Novartis
$76.49 /

+1.84 (+2.46%)

MRK Merck
$86.46 /

+0.59 (+0.69%)

IMAB I-Mab
$4.77 /

+0.17 (+3.70%)

GILD Gilead
$63.70 /

+1.07 (+1.71%)

AZN AstraZeneca
$54.47 /

+1.22 (+2.29%)

AMGN Amgen
$229.80 /

+3.76 (+1.66%)

RHHBY Roche
$39.05 /

+0.36 (+0.93%)

PFE Pfizer
$44.50 /

+0.35 (+0.79%)

NVS Novartis
$76.49 /

+1.84 (+2.46%)

MRTX Mirati Therapeutics
$69.30 /

+1.71 (+2.53%)

MRK Merck
$86.46 /

+0.59 (+0.69%)

IMAB I-Mab
$4.77 /

+0.17 (+3.70%)

GILD Gilead
$63.70 /

+1.07 (+1.71%)

AZN AstraZeneca
$54.47 /

+1.22 (+2.29%)

AMGN Amgen
$229.80 /

+3.76 (+1.66%)

PFE Pfizer
$44.50 /

+0.35 (+0.79%)

NVS Novartis
$76.49 /

+1.84 (+2.46%)

MRK Merck
$86.46 /

+0.59 (+0.69%)

GILD Gilead
$63.70 /

+1.07 (+1.71%)

AZN AstraZeneca
$54.47 /

+1.22 (+2.29%)

AMGN Amgen
$229.80 /

+3.76 (+1.66%)

Conference/Events
Guggenheim to hold a conference » 11:40
09/28/22
09/28
11:40
09/28/22
11:40
RPTX

Repare Therapeutics

$12.37 /

+0.51 (+4.30%)

, IMGN

ImmunoGen

$4.69 /

+0.05 (+1.08%)

, CNTA

Centessa

$4.55 /

+0.045 (+1.00%)

, KYMR

Kymera Therapeutics

$22.24 /

+0.62 (+2.87%)

, MGNX

MacroGenics

$3.64 /

+0.15 (+4.30%)

, SEEL

Seelos Therapeutics

$1.12 /

+0.07 (+6.67%)

, GLUE

Monte Rosa Therapeutics

$8.29 /

+0.525 (+6.76%)

, NTLA

Intellia Therapeutics

$57.48 /

+1.405 (+2.51%)

, EYPT

EyePoint

$7.38 /

+0.375 (+5.35%)

, IMPL

Impel Pharmaceuticals

$5.65 /

+0.22 (+4.05%)

, RUBY

Rubius Therapeutics

/

+

Nantucket Therapeutics…

Nantucket Therapeutics Conference to be held in New York on September 27-29. Webcast Link

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$1.12 /

+0.07 (+6.67%)

RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

MGNX MacroGenics
$3.64 /

+0.15 (+4.30%)

KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

IMGN ImmunoGen
$4.69 /

+0.05 (+1.08%)

GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

EYPT EyePoint
$7.38 /

+0.375 (+5.35%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

06/06/22 H.C. Wainwright
Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright
06/02/22 Piper Sandler
Piper ups Repare Therapeutics target after 'great deal' with Roche
04/12/22 Stifel
Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis'
04/12/22 Stifel
Repare Therapeutics downgraded to Hold from Buy at Stifel
IMGN ImmunoGen
$4.69 /

+0.05 (+1.08%)

09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
03/21/22 RBC Capital
ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital
CNTA Centessa
$4.55 /

+0.045 (+1.00%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
MGNX MacroGenics
$3.64 /

+0.15 (+4.30%)

09/12/22 H.C. Wainwright
MacroGenics price target lowered to $10 from $35 at H.C. Wainwright
08/29/22 Citi
MacroGenics price target raised to $16 from $13 at Citi
08/09/22 Barclays
MacroGenics price target lowered to $8 from $18 at Barclays
07/11/22 BTIG
MacroGenics price target lowered to $6 at BTIG
SEEL Seelos Therapeutics
$1.12 /

+0.07 (+6.67%)

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

08/15/22 Jefferies
Monte Rosa Therapeutics initiated with a Buy at Jefferies
05/11/22 Piper Sandler
Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler
04/28/22 Credit Suisse
Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse
04/08/22 Piper Sandler
Piper keeps Overweight rating on Monte Rosa Therapeutics after AACR abstract
NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

09/21/22 JPMorgan
JPMorgan starts Intellia with Overweight, adds to Focus List
09/21/22 JPMorgan
Intellia Therapeutics initiated with an Overweight at JPMorgan
09/19/22 JMP Securities
Intellia Therapeutics price target raised to $111 from $106 at JMP Securities
09/19/22 Citi
Citi keeps Sell rating, $50 target on Intellia Therapeutics after data
EYPT EyePoint
$7.38 /

+0.375 (+5.35%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
11/16/21 Cantor Fitzgerald
EyePoint stock movement unwarranted, says Cantor Fitzgerald
IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

08/24/22 JonesTrading
Impel Pharmaceuticals initiated with a Buy at JonesTrading
RUBY Rubius Therapeutics
/

+

09/13/22 Guggenheim
Rubius downgraded at Guggenheim after discontinuation of all clinical programs
09/13/22 Guggenheim
Rubius Therapeutics downgraded to Neutral from Buy at Guggenheim
05/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $8 from $15 at H.C. Wainwright
04/11/22 Morgan Stanley
Rubius Therapeutics price target lowered to $4 from $15 at Morgan Stanley
RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

MGNX MacroGenics
$3.64 /

+0.15 (+4.30%)

KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

IMGN ImmunoGen
$4.69 /

+0.05 (+1.08%)

GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

EYPT EyePoint
$7.38 /

+0.375 (+5.35%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

  • 02
    Dec
  • 17
    Nov
  • 28
    Oct
NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

SEEL Seelos Therapeutics
$1.12 /

+0.07 (+6.67%)

GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.